Abde Abukhdeir to Neoadjuvant Therapy
This is a "connection" page, showing publications Abde Abukhdeir has written about Neoadjuvant Therapy.
Connection Strength
0.177
-
FDA Approval Summary: Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf Injection for Subcutaneous Use in Patients with HER2-positive Breast Cancer. Clin Cancer Res. 2021 04 15; 27(8):2126-2129.
Score: 0.177